Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ac-AKY-2519

Radiopharmaceutical · Kills target cells, directed at B7-H3 (CD276) · developed by Aktis Oncology

Phase 1 Most advanced trial

AKTS Developer

1 Registered trials

What is Ac-AKY-2519?

Ac-AKY-2519 is a actinium-225 labeled radiopharmaceutical that carries a radioactive payload to B7-H3 expressing cells. It is being studied in castration-resistant metastatic prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Radiopharmaceutical
Targets: B7-H3 (CD276)
Mechanism: Kills target cells, directed at B7-H3 (CD276)
Therapy area: Oncology
Developer: Aktis Oncology, Inc. (AKTS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07581184	Phase 1	Castration Resistant Metastatic Prostate Cancer	Recruiting	AKTS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B7H3Castration Resistant Metastatic Prostate CancermCRPCmCRPC (Metastatic Castration-resistant Prostate Cancer)Prostate Cancer

Other drugs acting on CD276

GTB-5550 Phase 1 Ifinatamab Deruxtecan Phase 2

More from Aktis Oncology

Ac-AKY-1189 Phase 1 Cu-AKY-1189 Phase 1 Cu-AKY-2519 Phase 1

Sources

ClinicalTrials.gov NCT07581184

Updated Oct 11, 2026. Something wrong or missing? Report it on the AKTS page.

Follow AKTS, the company behind Ac-AKY-2519

See AKTS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AKTS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z